🚀 VC round data is live in beta, check it out!
Boan Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Boan Biotech and similar public comparables like Lyell Immunopharma, Supriya Lifescience, Fulcrum Therapeutics, Agomab Therapeutics and more.
Boan Biotech Overview
About Boan Biotech
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, metabolism, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Founded
2013
HQ
Employees
760
Website
Sectors
Financials (LTM)
EV
$578M
Boan Biotech Financials
Boan Biotech reported last 12-month revenue of $118M and EBITDA of $11M.
In the same LTM period, Boan Biotech generated $85M in gross profit, $11M in EBITDA, and $2M in net income.
Revenue (LTM)
Boan Biotech P&L
In the most recent fiscal year, Boan Biotech reported revenue of $106M and EBITDA of $26M.
Boan Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $118M | XXX | $106M | XXX | XXX | XXX |
| Gross Profit | $85M | XXX | $80M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $11M | XXX | $26M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $2M | XXX | $11M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $70M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Boan Biotech Stock Performance
Boan Biotech has current market cap of $558M, and enterprise value of $578M.
Market Cap Evolution
Boan Biotech's stock price is $0.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $578M | $558M | -3.3% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoan Biotech Valuation Multiples
Boan Biotech trades at 4.9x EV/Revenue multiple, and 51.1x EV/EBITDA.
EV / Revenue (LTM)
Boan Biotech Financial Valuation Multiples
As of April 19, 2026, Boan Biotech has market cap of $558M and EV of $578M.
Equity research analysts estimate Boan Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boan Biotech has a P/E ratio of 293.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $558M | XXX | $558M | XXX | XXX | XXX |
| EV (current) | $578M | XXX | $578M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 51.1x | XXX | 22.1x | XXX | XXX | XXX |
| EV/EBIT | 105.8x | XXX | 37.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 7.3x | XXX | XXX | XXX |
| P/E | 293.8x | XXX | 52.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Boan Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Boan Biotech Margins & Growth Rates
Boan Biotech's revenue in the last 12 month grew by 15%.
Boan Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Boan Biotech's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boan Biotech's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Boan Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 124% | XXX | (75%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 42% | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Boan Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Boan Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Lyell Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Agomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tectonic Therapeutic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boan Biotech M&A Activity
Boan Biotech acquired XXX companies to date.
Last acquisition by Boan Biotech was on XXXXXXXX, XXXXX. Boan Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Boan Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBoan Biotech Investment Activity
Boan Biotech invested in XXX companies to date.
Boan Biotech made its latest investment on XXXXXXXX, XXXXX. Boan Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Boan Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Boan Biotech
| When was Boan Biotech founded? | Boan Biotech was founded in 2013. |
| Where is Boan Biotech headquartered? | Boan Biotech is headquartered in China. |
| How many employees does Boan Biotech have? | As of today, Boan Biotech has over 760 employees. |
| Is Boan Biotech publicly listed? | Yes, Boan Biotech is a public company listed on HKEX. |
| What is the stock symbol of Boan Biotech? | Boan Biotech trades under 06955 ticker. |
| When did Boan Biotech go public? | Boan Biotech went public in 2022. |
| Who are competitors of Boan Biotech? | Boan Biotech main competitors are Lyell Immunopharma, Supriya Lifescience, Fulcrum Therapeutics, Agomab Therapeutics. |
| What is the current market cap of Boan Biotech? | Boan Biotech's current market cap is $558M. |
| What is the current revenue of Boan Biotech? | Boan Biotech's last 12 months revenue is $118M. |
| What is the current revenue growth of Boan Biotech? | Boan Biotech revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Boan Biotech? | Current revenue multiple of Boan Biotech is 4.9x. |
| Is Boan Biotech profitable? | Yes, Boan Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boan Biotech? | Boan Biotech's last 12 months EBITDA is $11M. |
| What is Boan Biotech's EBITDA margin? | Boan Biotech's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Boan Biotech? | Current EBITDA multiple of Boan Biotech is 51.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.